CAJ | 학술논문

目的：探讨酪氨酸激酶抑制剂 Erlotinib 联合放疗对鼻咽癌裸鼠移植瘤的作用。方法将鼻咽癌细胞株 CNE2接种于32只裸鼠后腿皮下，8 d 后肿瘤体积在100～200 mm 3之间，将裸鼠按体积大小随机分为4组：对照组、Erlotinib 组、放疗组和放疗＋Erlotinib 组，每组8只。分组第1天予以照射1次8 Gy，Erlotinib 分组第1天予以灌胃给药，1.6 mg／次，1次／d，连用2周。停药1周后处死动物，测量瘤块体积和重量，采用免疫组织化学法检测各组标本中 EGFR 和 p －EGFR 的表达情况，并进行统计学分析。结果对照组、Erlotinib 组、放疗组、放疗＋Erlotinib 组的瘤重分别为（2.60±1.51）、（1.56±0.67）、（0.71±0.42）、（0.48±0.31）g，放疗＋Erlotinib 组瘤重小于 Erlotinib 及放疗组（P ＝0.026，P ＝0.047）。各组 EGFR 表达无明显差异，p －EGFR 在放疗组明显增强，放疗＋Erlotinib 组阳性表达率最低。结论Erlotinib 通过抑制 EGFR 磷酸化增强了鼻咽癌的放射敏感性。
목적：탐토락안산격매억제제 Erlotinib 연합방료대비인암라서이식류적작용。방법장비인암세포주 CNE2접충우32지라서후퇴피하，8 d 후종류체적재100～200 mm 3지간，장라서안체적대소수궤분위4조：대조조、Erlotinib 조、방료조화방료＋Erlotinib 조，매조8지。분조제1천여이조사1차8 Gy，Erlotinib 분조제1천여이관위급약，1.6 mg／차，1차／d，련용2주。정약1주후처사동물，측량류괴체적화중량，채용면역조직화학법검측각조표본중 EGFR 화 p －EGFR 적표체정황，병진행통계학분석。결과대조조、Erlotinib 조、방료조、방료＋Erlotinib 조적류중분별위（2.60±1.51）、（1.56±0.67）、（0.71±0.42）、（0.48±0.31）g，방료＋Erlotinib 조류중소우 Erlotinib 급방료조（P ＝0.026，P ＝0.047）。각조 EGFR 표체무명현차이，p －EGFR 재방료조명현증강，방료＋Erlotinib 조양성표체솔최저。결론Erlotinib 통과억제 EGFR 린산화증강료비인암적방사민감성。
Objective To investigate the effects of radiotherapy combined with erlotinib on nasopharyngeal carci -noma (NPC) xenografts in nude mice.Methods The NPC cell lines CNE2 were injected s.c.into the hind legs of athy-mic nude mice.When tumor volume was approximately between 100 -200 mm 3 , nude mice were randomly divided into four groups: control, erlotinib, radiation and radiotherapy in combination with erlotinib groups .Radiotherapy was delive-red with 8 Gy in one time on the first day of randomization .Erlotinib was administered by oral gavage (1.6 mg once dai-ly) for 2 weeks.The nude mice were sacrificed 1 week after stopping the treatment , and the tumor size and weight were measured.The expression of epidermal growth factor receptor (EGFR) and phosphorylated EGFR (p -EGFR) were de-tected in histologic sections of xenografts by immunohistochemistry and analyzed by statistical method .Results Erlotinib combined with radiotherapy could significantly slow down tumor growth .Tumor weights in control group , erlotinib group, radiotherapy group and radiotherapy in combination with erlotinib group were (2.60 ±1.51), (1.56 ±0.67), (0.71 ± 0.42) and (0.48 ±0.31) g, respectively.Compared with erlotinib group or radiotherapy group , radiotherapy in combina-tion with erlotinib group significantly inhibited the growth of xenografts in nude mice (P =0.026, P =0.047).There was no significant difference in expression of EGFR among the 6 groups.Conclusion Erlotinib can enhance radiosensitivity of NPC by the inhibition of EGFR phosphorylation .